{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:00:17Z","timestamp":1779105617849,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T00:00:00Z","timestamp":1628726400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"the japan agency for medical research","award":["grant number 20ck0106537h0001"],"award-info":[{"award-number":["grant number 20ck0106537h0001"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s13577-021-00589-x","type":"journal-article","created":{"date-parts":[[2021,8,12]],"date-time":"2021-08-12T10:03:36Z","timestamp":1628762616000},"page":"1911-1918","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Establishment and characterization of NCC-MFS4-C1: a novel patient-derived cell line of myxofibrosarcoma"],"prefix":"10.1007","volume":"34","author":[{"given":"Yuki","family":"Yoshimatsu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rei","family":"Noguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryuto","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yooksil","family":"Sin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Sugaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shintaro","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6405-7792","authenticated-orcid":false,"given":"Tadashi","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,8,12]]},"reference":[{"key":"589_CR1","doi-asserted-by":"crossref","unstructured":"Board WCoTE. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2):181\u2013185","DOI":"10.1111\/his.14091"},{"key":"589_CR2","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1200\/JCO.2017.75.3467","volume":"36","author":"BC Widemann","year":"2018","unstructured":"Widemann BC, Italiano A. Biology and management of undifferentiated pleomorphic sarcoma, myxofibrosarcoma, and malignant peripheral nerve sheath tumors: state of the art and perspectives. J Clin Oncol. 2018;36:160\u20137.","journal-title":"J Clin Oncol"},{"key":"589_CR3","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1038\/ng.619","volume":"42","author":"J Barretina","year":"2010","unstructured":"Barretina J, Taylor BS, Banerji S, et al. Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet. 2010;42:715\u201321.","journal-title":"Nat Genet"},{"key":"589_CR4","doi-asserted-by":"crossref","unstructured":"Mentzel T, Calonje E, Wadden C, et al. Myxofibrosarcoma. Clinicopathologic analysis of 75 cases with emphasis on the lowgrade variant. Am J Surg Pathol. 1996;20:391\u2013405.","DOI":"10.1097\/00000478-199604000-00001"},{"key":"589_CR5","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1245\/s10434-010-1341-4","volume":"18","author":"R Sanfilippo","year":"2011","unstructured":"Sanfilippo R, Miceli R, Grosso F, et al. Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2011;18:720\u20135.","journal-title":"Ann Surg Oncol"},{"key":"589_CR6","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.soc.2016.05.008","volume":"25","author":"CL Roland","year":"2016","unstructured":"Roland CL, Wang WL, Lazar AJ, Torres KE. Myxofibrosarcoma. Surg Oncol Clin N Am. 2016;25:775\u201388.","journal-title":"Surg Oncol Clin N Am"},{"key":"589_CR7","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1002\/jso.23708","volume":"110","author":"S Iwata","year":"2014","unstructured":"Iwata S, Yonemoto T, Araki A, et al. Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol. 2014;110:707\u201311.","journal-title":"J Surg Oncol"},{"key":"589_CR8","doi-asserted-by":"publisher","first-page":"W193","DOI":"10.2214\/AJR.05.1130","volume":"188","author":"B Waters","year":"2007","unstructured":"Waters B, Panicek DM, Lefkowitz RA, et al. Low-grade myxofibrosarcoma: CT and MRI patterns in recurrent disease. AJR Am J Roentgenol. 2007;188:W193\u20138.","journal-title":"AJR Am J Roentgenol"},{"key":"589_CR9","doi-asserted-by":"crossref","unstructured":"Dewan V, Darbyshire A, Sumathi V, Jeys L, Grimer R. Prognostic and survival factors in myxofibrosarcomas. Sarcoma. 2012;2012:830879.","DOI":"10.1155\/2012\/830879"},{"key":"589_CR10","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1245\/s10434-015-5063-5","volume":"23","author":"AY Lee","year":"2016","unstructured":"Lee AY, Agaram NP, Qin LX, et al. Optimal percent myxoid component to predict outcome in high-grade myxofibrosarcoma and undifferentiated pleomorphic sarcoma. Ann Surg Oncol. 2016;23:818\u201325.","journal-title":"Ann Surg Oncol"},{"key":"589_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.humpath.2004.01.016","volume":"35","author":"HY Huang","year":"2004","unstructured":"Huang HY, Lal P, Qin J, Brennan MF, Antonescu CR. Low-grade myxofibrosarcoma: a clinicopathologic analysis of 49 cases treated at a single institution with simultaneous assessment of the efficacy of 3-tier and 4-tier grading systems. Hum Pathol. 2004;35:612\u201321.","journal-title":"Hum Pathol"},{"key":"589_CR12","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1002\/cncr.26296","volume":"118","author":"RW Mutter","year":"2012","unstructured":"Mutter RW, Singer S, Zhang Z, Brennan MF, Alektiar KM. The enigma of myxofibrosarcoma of the extremity. Cancer. 2012;118:518\u201327.","journal-title":"Cancer"},{"key":"589_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1245\/s10434-012-2572-3","volume":"20","author":"NJ Look Hong","year":"2013","unstructured":"Look Hong NJ, Hornicek FJ, Raskin KA, et al. Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2013;20:80\u20136.","journal-title":"Ann Surg Oncol"},{"key":"589_CR14","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s13577-010-0006-8","volume":"24","author":"S Saito","year":"2011","unstructured":"Saito S, Morita K, Kohara A, et al. Use of BAC array CGH for evaluation of chromosomal stability of clinically used human mesenchymal stem cells and of cancer cell lines. Hum Cell. 2011;24:2\u20138.","journal-title":"Hum Cell"},{"key":"589_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.gde.2019.02.007","volume":"54","author":"YY Tseng","year":"2019","unstructured":"Tseng YY, Boehm JS. From cell lines to living biosensors: new opportunities to prioritize cancer dependencies using ex vivo tumor cultures. Curr Opin Genet Dev. 2019;54:33\u201340.","journal-title":"Curr Opin Genet Dev"},{"key":"589_CR16","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41568-018-0095-3","volume":"19","author":"U Ben-David","year":"2019","unstructured":"Ben-David U, Beroukhim R, Golub TR. Genomic evolution of cancer models: perils and opportunities. Nat Rev Cancer. 2019;19:97\u2013109.","journal-title":"Nat Rev Cancer"},{"key":"589_CR17","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1016\/j.cell.2013.08.003","volume":"154","author":"A Basu","year":"2013","unstructured":"Basu A, Bodycombe NE, Cheah JH, et al. An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules. Cell. 2013;154:1151\u201361.","journal-title":"Cell"},{"key":"589_CR18","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483:603\u20137.","journal-title":"Nature"},{"key":"589_CR19","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang W, Soares J, Greninger P, et al. Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013;41:D955\u201361.","journal-title":"Nucleic Acids Res"},{"key":"589_CR20","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6:813\u201323.","journal-title":"Nat Rev Cancer"},{"key":"589_CR21","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-15-0189","volume":"14","author":"A Goodspeed","year":"2016","unstructured":"Goodspeed A, Heiser LM, Gray JW, Costello JC. Tumor-derived cell lines as molecular models of cancer pharmacogenomics. Mol Cancer Res. 2016;14:3\u201313.","journal-title":"Mol Cancer Res"},{"key":"589_CR22","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/cells8020157","volume":"8","author":"E Hattori","year":"2019","unstructured":"Hattori E, Oyama R, Kondo T. Systematic Review of the Current Status of Human Sarcoma Cell Lines. Cells. 2019;8:157.","journal-title":"Cells"},{"key":"589_CR23","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7171\/jbt.18-2902-002","volume":"29","author":"A Bairoch","year":"2018","unstructured":"Bairoch A. The Cellosaurus, a cell-line knowledge resource. J Biomol Tech. 2018;29:25\u201338.","journal-title":"J Biomol Tech"},{"key":"589_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.cancergencyto.2005.02.003","volume":"161","author":"H Kawashima","year":"2005","unstructured":"Kawashima H, Ogose A, Gu W, et al. Establishment and characterization of a novel myxofibrosarcoma cell line. Cancer Genet Cytogenet. 2005;161:28\u201335.","journal-title":"Cancer Genet Cytogenet"},{"key":"589_CR25","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/1756-9966-28-44","volume":"28","author":"T Ariizumi","year":"2009","unstructured":"Ariizumi T, Ogose A, Kawashima H, Hotta T, Umezu H, Endo N. Multinucleation followed by an acytokinetic cell division in myxofibrosarcoma with giant cell proliferation. J Exp Clin Cancer Res. 2009;28:44.","journal-title":"J Exp Clin Cancer Res"},{"key":"589_CR26","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1002\/jcb.21073","volume":"100","author":"V Moneo","year":"2007","unstructured":"Moneo V, Serelde BG, Fominaya J, et al. Extreme sensitivity to Yondelis (Trabectedin, ET-743) in low passaged sarcoma cell lines correlates with mutated p53. J Cell Biochem. 2007;100:339\u201348.","journal-title":"J Cell Biochem"},{"key":"589_CR27","doi-asserted-by":"crossref","unstructured":"Miserocchi G, De Vita A, Mercatali L, et al. Characterization and drug sensitivity of a new high-grade myxofibrosarcoma cell line. Cells. 2018;7.(11):186.","DOI":"10.3390\/cells7110186"},{"key":"589_CR28","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1186\/1471-2407-13-563","volume":"13","author":"B Lohberger","year":"2013","unstructured":"Lohberger B, Stuendl N, Wolf E, Liegl-Atzwanger B, Leithner A, Rinner B. The novel myxofibrosarcoma cell line MUG-Myx1 expresses a tumourigenic stem-like cell population with high aldehyde dehydrogenase 1 activity. BMC Cancer. 2013;13:563.","journal-title":"BMC Cancer"},{"key":"589_CR29","doi-asserted-by":"publisher","first-page":"44700","DOI":"10.1038\/srep44700","volume":"7","author":"B Lohberger","year":"2017","unstructured":"Lohberger B, Stuendl N, Leithner A, et al. Establishment of a novel cellular model for myxofibrosarcoma heterogeneity. Sci Rep. 2017;7:44700.","journal-title":"Sci Rep"},{"key":"589_CR30","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1007\/s13577-018-00233-1","volume":"32","author":"F Kito","year":"2019","unstructured":"Kito F, Oyama R, Sakumoto M, et al. Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma. Hum Cell. 2019;32:214\u201322.","journal-title":"Hum Cell"},{"key":"589_CR31","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1007\/s13577-020-00420-z","volume":"34","author":"R Noguchi","year":"2021","unstructured":"Noguchi R, Yoshimatsu Y, Ono T, et al. Establishment and characterization of NCC-MFS2-C1: a novel patient-derived cancer cell line of myxofibrosarcoma. Hum Cell. 2021;34:246\u201353.","journal-title":"Hum Cell"},{"key":"589_CR32","doi-asserted-by":"crossref","unstructured":"Tsuchiya R, Yoshimatsu Y, Noguchi R, et al. Establishment and characterization of NCC-MFS3-C1: a novel patient-derived cell line of myxofibrosarcoma. Hum Cell. 2021;34(4):1266\u20131273.","DOI":"10.1007\/s13577-021-00548-6"},{"key":"589_CR33","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1002\/ijc.27931","volume":"132","author":"A Capes-Davis","year":"2013","unstructured":"Capes-Davis A, Reid YA, Kline MC, et al. Match criteria for human cell line authentication: where do we draw the line? Int J Cancer. 2013;132:2510\u20139.","journal-title":"Int J Cancer"},{"key":"589_CR34","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/AAC.12.1.11","volume":"12","author":"A Billiau","year":"1977","unstructured":"Billiau A, Edy VG, Heremans H, et al. Human interferon: mass production in a newly established cell line, MG-63. Antimicrob Agents Chemother. 1977;12:11\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"589_CR35","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"S Gandolfi","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev. 2017;36:561\u201384.","journal-title":"Cancer Metastasis Rev"},{"key":"589_CR36","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1158\/1078-0432.CCR-11-3077","volume":"18","author":"CF Li","year":"2012","unstructured":"Li CF, Wang JM, Kang HY, et al. Characterization of gene amplification-driven SKP2 overexpression in myxofibrosarcoma: potential implications in tumor progression and therapeutics. Clin Cancer Res. 2012;18:1598\u2013610.","journal-title":"Clin Cancer Res"},{"key":"589_CR37","first-page":"22","volume":"6","author":"L Barbarotta","year":"2015","unstructured":"Barbarotta L, Hurley K. Romidepsin for the treatment of peripheral T-Cell lymphoma. J Adv Pract Oncol. 2015;6:22\u201336.","journal-title":"J Adv Pract Oncol"},{"key":"589_CR38","first-page":"464","volume":"25","author":"A Kawarazaki","year":"2020","unstructured":"Kawarazaki A, Horinaka M, Yasuda S, Kawashima H, Numajiri T, Sakai T. The HDAC inhibitor OBP-801 suppresses the growth of myxofibrosarcoma cells. J BUON. 2020;25:464\u201371.","journal-title":"J BUON"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-021-00589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-021-00589-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-021-00589-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,5]],"date-time":"2021-10-05T07:40:20Z","timestamp":1633419620000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-021-00589-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["589"],"URL":"https:\/\/doi.org\/10.1007\/s13577-021-00589-x","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,8,12]]},"assertion":[{"value":"1 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 August 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The ethical committee of the National Cancer Center approved the use of clinical materials for this study (approval number 2004\u2013050).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for publication was provided by the patient.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}